Estepan Ian Michael 4

What Happened
Ian Estepan, Chief Operating Officer of Sarepta Therapeutics, had a total of 1,619 shares disposed (withheld) by the company to satisfy tax withholding when restricted stock units vested. The transactions on March 9, 2026 show 1,036 shares withheld at $16.95 ($17,560) and 583 shares withheld at $16.95 ($9,882), for a combined value of $27,442. This is a routine tax-withholding disposition rather than an open-market sale.

Key Details

• Transaction dates/prices: 2026-03-09 — 1,036 shares @ $16.95 and 583 shares @ $16.95.
• Total shares withheld/disposed: 1,619; total value ≈ $27,442.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnotes: F1 — withholding for RSUs granted Mar 7, 2022; F2 — withholding for RSUs granted Mar 6, 2023.
• Transaction code: F (payment of exercise price or tax liability via share withholding).
• Filing timeliness: Transaction reported on Form 4 filed 2026-03-11 for a 2026-03-09 transaction — filed within the typical 2-business-day window.

Context
Withholding shares to cover taxes on vested RSUs is common and generally a neutral, administrative event — it does not indicate an intentional market sale by the insider. This was effectively a cashless settlement (company retained shares to meet tax obligations) rather than a discretionary sale or purchase.